Article Details

AB Science communicates results from Phase 3 study evaluating masitinib in prostate cancer

Retrieved on: 2021-05-26 17:15:00

Tags for this article:

Click the tags to see associated articles and topics

AB Science communicates results from Phase 3 study evaluating masitinib in prostate cancer. View article details on hiswai:

Excerpt

Metastatic prostate cancer is still an unmet medical need. The median survival of patients with metastatic prostate cancer is around 2 years and the 5- ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up